UCB Muscle Disease Drug Wins FDA Nod on Heels of Rival’s Regulatory Approval

The FDA approved UCB’s Rystiggo for treating generalized myasthenia gravis. Drugs are already available for the rare neuromuscular disorder, but Rystiggo’s approval includes treatment of a subset of patients not addressed by other products.